In 2020,  we advised a portfolio of a top EU PE house for its progressive acquisition of a Chinese pharmaceuitical manufacturer. The effort provided an immediate China operation with possibiities to supply both China and global demands. Due to stringent Chinese regulartions, such a deal created a reference model for other pharma and CDMO players to enter China market.